In major neuropsychiatric illnesses, such as schizophrenia, substance use disorders, and Parkinson's disease, cognitive and behavioral correlates of clinical deterioration are complex. Insufficient knowledge of pathophysiological mechanisms in these conditions is a key impediment to directing the development of disease-modifying treatments, and derives, in part, from an incomplete understanding of normative neural systems operations. Illness-associated alterations in neuroimaging measures of multifaceted neurotransmitter systems, such as that of dopamine, and of composite interactional functional imaging metrics, such as magnetic resonance imaging (MRI)-based interregional correlations in blood oxygen level-dependent signal, have increasingly been investigated as potential discovery-leading phenotypes. However, these important findings rely on systems-level signals that are often challenging to interpret in isolation, and integrative work leveraging complementary imaging modalities and experimental tools in concert is critical to meaningfully advance the comprehension of these neural signals in both health states and disease states.
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For instance, the examination of low frequency, spontaneous interregional covariation in blood oxygen leveldependent signal during resting states with functional MRI (fMRI) has established reliable, large-scale neuroanatomically described network components (1) . Preclinical data have indicated that such "resting-state connectivity" corresponds to ongoing fluctuations in local field potential and that these fluctuations reflect topographical components of neuronal activity coherence (2); however, specific drivers of systemslevel variation in each of these components remain inadequately elucidated. Thus, despite intriguing findings in patient groups (3), the biological significance of most variability in resting-state fMRI network components across individuals is unclear. Neuroanatomical literature in nonhuman primates has documented the broad extent of dopaminergic projections across mesolimbic, mesocortical, and nigrostriatal pathways as well as the prominence of organized corticostriatal recurrent circuitry (4), suggesting that striatal dopamine system properties may be related to the activity of considerable swaths of cortex. If so, it is possible-though not necessarily the casethat such properties are linked to the type of cortical activity indexed by interindividual differences in fMRI-assayed restingstate networks.
In work bridging resting-state fMRI and positron emission tomography measurements, McCutcheon et al. (5) provide a valuable step toward characterizing striatal dopamine-related variability in resting-state network connectivity. By examining, in two separate experiments, the resting-state fMRI correlates of both limbic striatal dopamine synthesis capacity (DOPA decarboxylase activity) and dopamine release (D 2 receptor ligand displacement), this study offers strong evidence that basal ganglia neurochemical traits do align with wider network function in the healthy, living human brain at rest. Specifically, a metric of salience network coherence showed positive and negative correlations with limbic striatal dopamine synthesis capacity and dexamphetamine-induced dopamine release capacity, respectively. These findings obtained in two sets of over 20 volunteers and showing substantial effect sizes (Pearson's r 2 values of .26 and .18 for synthesis and release capacity, respectively) help validate the notion that salience network measurements contain (but are not synonymous with) important dopamine systems information. The opposing direction of the release relative to synthesis findings was unexpected by McCutcheon et al. (5) and is difficult to predict from existing pharmacological fMRI literature, though in at least one previous study, amphetamineinduced dopamine release corresponded to connectivity decrements in salience executive networks (6), potentially consistent with the direction if not scope of the release findings here. Furthermore, previous experimentation has identified independence of these two measurements when performed in the same individuals (7), indicating that a unidimensional model of basal ganglia function is not sufficient and suggesting that concurrent study of different dopaminergic metrics may be needed to more fully explain variance in large-scale, restingstate network functions.
Given the broad span of meso-cortico-striatal loops and regional importance of dopamine systems to executive, motor, limbic, and other circuitry throughout the cortex, appreciating differential contributions of dopamine systems function to the basal physiology of diverse canonical neural networks and how each of these relationships shapes behavior is a daunting task. By isolating four such networks from resting-state fMRI data and testing for correlations with limbic striatal dopamine positron emission tomography parameters, McCutcheon et al. (5) found that associations with limbic striatal dopamine synthesis and release occurred more consistently with the strength of the salience network than with strength of the default mode, sensorimotor, or visual networks. If this specificity is confirmed to be statistically robust, it may present novel insight into the overall signal properties of these large networks and potential biological biases in their regulation.
McCutcheon et al. (5) used a graph theory approach to elaborate on comparative dopaminergic correlates of restingstate networks. When parcellated brain regions were classified as to whether they were network hubs (regions showing strong signal correlations with many other regions, participating in a large number of shortest paths between other regions, and showing more connections outside of its local cluster), McCutcheon et al. (5) found that salience network regions showing associations with limbic striatal dopamine synthesis were more likely to be network hubs than would be expected by chance. This intriguing finding raises questions about the organization of dopamine-linked networks, which could ultimately guide computational models of disease or biomarker development in some way but currently require further study. Whether hubs as defined in this work are more densely innervated by dopaminergic inputs or are more likely to send efferent projections to the basal ganglia is unknown and constitutes an important anatomical hypothesis to test. As this and other reductive complex network analytic techniques are increasingly used in highly dimensional functional data, it will be imperative to engage in experimentation that tethers observations to known biological processes (e.g., dopaminergic mechanisms) and contexts to promote consequential and actionable advancement of neuroscientific knowledge, particularly as related to disease.
Importantly, what can these integrated neurochemicalneurofunctional findings tell us about approaching the pathophysiology of neuropsychiatric disorders? Certainly, as McCutcheon et al. (5) and others have pointed out, these systems-i.e., dopaminergic basal ganglia and salience networks-show alterations in several different patient groups and have been particularly well-implicated in some illnesses, such as schizophrenia (8, 9) . Understanding the normative structure of these key neuroimaging variables is an important foundation upon which to build models of illness and develop biomarkers. Ultimately, these must be tested with comprehensive and carefully integrated multimodal experimentation in patients, as illness-related neural dynamics are anticipated to be complex. For example, previous work has demonstrated that relationships between limbic striatal D 2/3 dopamine receptor function and meso-cortico-striatal resting-state network connectivity may be markedly different in certain patient populations (10) , which suggests that the same could be true for dopamine synthesis and release capacities.
In sum, the results reported by McCutcheon et al. (5) integrate neurochemical and neurofunctional experimentation in humans. Such multimodal data, along with advanced computational approaches, are increasingly needed to address unanswered mechanistic questions about systems-level functioning in health and disease.
